Log in

NASDAQ:SRTSSensus Healthcare Stock Price, Forecast & News

$2.50
+0.09 (+3.73 %)
(As of 04/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.41
Now: $2.50
$2.70
50-Day Range
$2.25
MA: $3.42
$4.64
52-Week Range
$2.10
Now: $2.50
$7.00
Volume17,092 shs
Average Volume33,016 shs
Market Capitalization$41.23 million
P/E RatioN/A
Dividend YieldN/A
Beta0.3
Sensus Healthcare, Inc. manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sculptura product, a proprietary robotic intraoperative radiation therapy system that uses patented Beam Sculpting capabilities to treat various cancers during surgery; and Sentinel service program, which offers its customers protection for their systems. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons, eye shields, and disposable applicator tips, which are used to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was founded in 2010 and is headquartered in Boca Raton, Florida.
Read More
Sensus Healthcare logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.57 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SRTS
CUSIPN/A
Phone561-922-5808

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$27.26 million
Book Value$1.70 per share

Profitability

Net Income$-1,700,000.00

Miscellaneous

Employees48
Market Cap$41.23 million
Next Earnings Date5/14/2020 (Estimated)
OptionableNot Optionable

Receive SRTS News and Ratings via Email

Sign-up to receive the latest news and ratings for SRTS and its competitors with MarketBeat's FREE daily newsletter.


Sensus Healthcare (NASDAQ:SRTS) Frequently Asked Questions

How has Sensus Healthcare's stock been impacted by COVID-19 (Coronavirus)?

Sensus Healthcare's stock was trading at $3.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SRTS stock has decreased by 23.1% and is now trading at $2.50. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Sensus Healthcare?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sensus Healthcare in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sensus Healthcare.

When is Sensus Healthcare's next earnings date?

Sensus Healthcare is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Sensus Healthcare.

How were Sensus Healthcare's earnings last quarter?

Sensus Healthcare Inc (NASDAQ:SRTS) issued its quarterly earnings results on Thursday, February, 13th. The company reported $0.06 EPS for the quarter, beating analysts' consensus estimates of $0.03 by $0.03. The business earned $8.51 million during the quarter, compared to analyst estimates of $8.45 million. Sensus Healthcare had a negative net margin of 6.24% and a negative return on equity of 6.22%. View Sensus Healthcare's earnings history.

What price target have analysts set for SRTS?

4 brokerages have issued 1-year price objectives for Sensus Healthcare's shares. Their forecasts range from $5.50 to $11.00. On average, they anticipate Sensus Healthcare's share price to reach $7.63 in the next twelve months. This suggests a possible upside of 205.0% from the stock's current price. View analysts' price targets for Sensus Healthcare.

What are Wall Street analysts saying about Sensus Healthcare stock?

Here are some recent quotes from research analysts about Sensus Healthcare stock:
  • 1. HC Wainwright analysts commented, "Our price target is derived from an EV-to-sales multiple of 6.0x and TTM revenue ($1.57/share). Risks include, but are not limited to: (1) failure of SRT and IORT systems to achieve commercial success due to reimbursement, penetration rate, and/or competition; (2) failure of other potential pipeline products; and (3) potential dilution risk. Sensus Healthcare, Inc. May 13, 2019 H.C. WAINWRIGHT & CO." (5/13/2019)
  • 2. Maxim Group analysts commented, "Sensus reported lower-than-expected 1Q19 revenue and a wider-than- expected GAAP EPS loss due to a delayed shipment of seven SRT-100 Vision systems to its largest customer. We are slightly reducing our estimates to reflect the miss and a lower 2019 growth rate." (5/10/2019)

Has Sensus Healthcare been receiving favorable news coverage?

Press coverage about SRTS stock has trended very negative this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sensus Healthcare earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutSensus Healthcare.

Who are some of Sensus Healthcare's key competitors?

What other stocks do shareholders of Sensus Healthcare own?

Who are Sensus Healthcare's key executives?

Sensus Healthcare's management team includes the following people:
  • Mr. Joseph C. Sardano, Chairman, CEO & Pres (Age 66)
  • Mr. Arthur R. Levine, Chief Financial Officer (Age 61)
  • Mr. Kalman Fishman, COO & CTO (Age 48)
  • Dr. Ziv Karni, Chief Scientific Officer (Age 74)
  • Mr. Michael Sardano, VP, Gen. Counsel, Corp. Sec. and Director of Governance & Regulatory (Age 30)

When did Sensus Healthcare IPO?

(SRTS) raised $20 million in an initial public offering on Wednesday, March 30th 2016. The company issued 1,800,000 shares at $10.00-$12.00 per share. Joseph Gunnar and Feltl and Company acted as the underwriters for the IPO and Neidiger, Tucker, Bruner was co-manager.

What is Sensus Healthcare's stock symbol?

Sensus Healthcare trades on the NASDAQ under the ticker symbol "SRTS."

How do I buy shares of Sensus Healthcare?

Shares of SRTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sensus Healthcare's stock price today?

One share of SRTS stock can currently be purchased for approximately $2.50.

How big of a company is Sensus Healthcare?

Sensus Healthcare has a market capitalization of $41.23 million and generates $27.26 million in revenue each year. The company earns $-1,700,000.00 in net income (profit) each year or ($0.10) on an earnings per share basis. Sensus Healthcare employs 48 workers across the globe. View additional information about Sensus Healthcare.

What is Sensus Healthcare's official website?

The official website for Sensus Healthcare is http://www.sensushealthcare.com/.

How can I contact Sensus Healthcare?

Sensus Healthcare's mailing address is 851 BROKEN SOUND PARKWAY NW SUITE 215, BOCA RATON FL, 33487. The company can be reached via phone at 561-922-5808 or via email at [email protected]

This page was last updated on 4/4/2020 by MarketBeat.com Staff

Featured Article: What are gap-down stocks?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel